This is the authors' abstract. We don't add key points for this paper.
MobiCT is a bioinformatics pipeline designed to detect ultra-low-frequency variants present in cell-free DNA samples using unique molecular identifier (UMI). The pipeline is composed of three main stages: (i) UMI deduplication, (ii) alignment to reference genome, and (iii) variant calling. It has been validated using a range of cancer patients and control samples, demonstrating sensitivity, precision, and F1-score around 90%. Implemented in Nextflow, following the nf-core guidelines, MobiCT ensures reliability and reproducibility, making it suitable for both research and clinical applications.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cabello-Aguilar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: